Search

Date 2018 Author/Creator Kebenko, Maxim

1. A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors. (3rd August 2018)

Authors:
Kebenko, Maxim; Goebeler, Marie-Elisabeth; Wolf, Martin; Hasenburg, Annette; Seggewiss-Bernhardt, Ruth; Ritter, Barbara; Rautenberg, Beate; Atanackovic, Djordje; Kratzer, Andrea; Rottman, James B.; Friedrich, Matthias; Vieser, Eva; Elm, Stefanie; Patzak, Ingrid; Wessiepe, Dorothea; Stienen, Sabin...
Journal:
Oncoimmunology
Issue:
Volume 7:Number 8(2018)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17‐10 CIARA trial). (30th October 2018)

Authors:
Krauter, Jürgen; Fiedler, Walter; Schlenk, Richard F.; Paschka, Peter; Thol, Felicitas; Lübbert, Michael; Wattad, Mohammed; Verbeek, Mareike; Könecke, Christian; Neuhaus, Barbara; Papkalla, Armin; Kebenko, Maxim; Janning, Melanie; Döhner, Konstanze; Gaidzik, Verena I.; Becker, Heiko; Greil, Chris...
Journal:
British journal of haematology
Issue:
Volume 183:Number 2(2018)
Page Start:
235
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search